

09/608, 892

(FILE 'HOME' ENTERED AT 12:35:33 ON 15 MAY 2002)

FILE 'REGISTRY' ENTERED AT 12:35:47 ON 15 MAY 2002

L1 1 S GDYVS/SQEP

FILE 'CAPLUS' ENTERED AT 12:36:50 ON 15 MAY 2002

L2 1 S L1

FILE 'REGISTRY' ENTERED AT 12:37:23 ON 15 MAY 2002

L3 1 S ETVNF/SQEP

FILE 'CAPLUS' ENTERED AT 12:37:49 ON 15 MAY 2002

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 12:38:32 ON 15 MAY 2002

L5 0 S (124219-00-7P OR 148719-50-0P OR 169249-03-0P OR 174641-93-1P

L6 10 S (124219-00-7 OR 148719-50-0 OR 169249-03-0 OR 174641-93-1 OR

FILE 'CAPLUS, USPATFULL' ENTERED AT 12:40:49 ON 15 MAY 2002

L7 51 S L6

FILE 'REGISTRY' ENTERED AT 12:41:39 ON 15 MAY 2002

FILE 'REGISTRY' ENTERED AT 12:42:19 ON 15 MAY 2002

L8 1 S (124219-00-7)/RN

=>

L7 ANSWER 51 OF 51 USPATFULL
AN 90:7741 USPATFULL
TI Biologically active peptides which inhibit toxoplasma multiplication
IN Suzuki, Naoyoshi, Tokyo, Japan
Osaki, Humio, Kobe, Japan
PA Nippon Mining Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 4897463 19900130
AI US 1988-291039 19881228 (7)
PRAI JP 1987-330142 19871228
DT Utility
FS Granted
LN.CNT 578
INCL INCLM: 530/329.000
INCLS: 530/330.000
NCL NCLM: 530/329.000
NCLS: 530/330.000
IC [4]
ICM: C07K007-06
EXF 530/329; 530/330; 514/17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 51 hitrn

L7 ANSWER 51 OF 51 USPATFULL
IT 124219-00-7P *see 85*
(prepn. of, as immunoregulator for combating toxoplasma)

L8 1 (124219-00-7)/RN

=> d seq3

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

SEQ3 1 Asp-Asp-Asp-Asp-Asp

L10 ANSWER 4 OF 4 USPATFULL
 AN 95:99132 USPATFULL
 TI Physiologically active peptide having immunoregulatory activities
 IN Suzuki, Naoyoshi, Tokyo, Japan
 PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
 PI US 5464819 19951107
 AI US 1991-729353 19910712 (7)
 PRAI JP 1990-182714 19900712
 DT Utility
 FS Granted
 LN.CNT 1134
 INCL INCLM: 514/016.000
 INCLS: 514/017.000; 514/018.000; 514/019.000; 530/329.000; 530/330.000;
 530/331.000
 NCL NCLM: 514/016.000
 NCLS: 514/017.000; 514/018.000; 514/019.000; 530/329.000; 530/330.000;
 530/331.000
 IC [6]
 ICM: A61K038-00
 ICS: C07K005-00; C07K007-00; C07K017-00
 EXF 514/16; 514/17; 514/18; 514/19; 530/329; 530/330; 530/331
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
 AB . . . or inhibit prodn. of cellular proteins. Many of the peptides of
 the invention may be produced in large quantity by **recombinant**
 techniques and formulated in culture medium to produce the desired effect
 on cultured cells and tissues. Certain of the libraries of the invention
 and the peptides identified in them are particularly useful in
 concatamer-based **recombinant** expression methods.
 IT 124219-00-7P 148719-50-0P 169249-03-0P
 174641-93-1P 204197-97-7P 211629-12-8P
 273397-53-8P 387819-90-1P 387819-91-2P
 387819-92-3P 387819-93-4P 387819-94-5P 387819-95-6P
 387819-96-7P 387819-97-8P 387819-98-9P 387819-99-0P 387820-00-0P
 387820-01-1P 387820-02-2P 387820-03-3P 387820-04-4P 387820-05-5P
 387820-06-6P 387820-07-7P 387820-08-8P 387820-09-9P 387820-10-2P
 387820-11-3P 387820-12-4P 387820-13-5P 387820-14-6P 387820-15-7P
 387820-16-8P 387820-17-9P 387820-18-0P 387820-19-1P 387820-20-4P
 387820-21-5P 387820-22-6P 387820-23-7P 387820-24-8P 387820-25-9P
 387820-26-0P 387820-27-1P 387820-28-2P 387820-29-3P 387820-30-6P
 387820-31-7P 387820-32-8P 387820-33-9P 387820-34-0P 387820-35-1P
 387820-36-2P 387820-37-3P 387820-38-4P 387820-39-5P 387820-40-8P
 387820-41-9P 387820-42-0P 387820-43-1P 387820-44-2P 387820-45-3P
 387820-46-4P 387820-47-5P 387820-48-6P 387820-49-7P 387820-50-0P
 387820-51-1P 387820-52-2P 387820-53-3P 387820-54-4P 387820-55-5P
 387820-56-6P 387820-57-7P 387820-58-8P 387820-59-9P 387820-60-2P
 387820-61-3P 387820-62-4P 387820-63-5P 387820-64-6P 387820-65-7P
 387820-66-8P 387820-67-9P 387820-68-0P 387820-69-1P 387820-70-4P
 387820-71-5P 387820-72-6P 387820-73-7P 387820-74-8P 387820-75-9P
 387820-76-0P
 RL: BUU (Biological use, unclassified); CPN (Combinatorial preparation);
 PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study);
 PREP (Preparation); USES (Uses)
 (protein sequence; synthesis of peptide libraries for use in culture
 media)

=>

L5 ANSWER 4 OF 4 USPATFULL
AN 95:99132 USPATFULL
TI Physiologically active peptide having immunoregulatory activities
IN Suzuki, Naoyoshi, Tokyo, Japan
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
PI US 5464819 19951107
AI US 1991-729353 19910712 (7)
PRAI JP 1990-182714 19900712
DT Utility
FS Granted
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Huff, Sheela J.
LREP Birch, Stewart, Kolasch & Birch
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1134
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD Further, if desired, the physiologically active peptide of the present invention can also be produced by a **recombinant** DNA technique, utilizing a DNA coding for each peptide in combination with an appropriate host vector system.
IT 57738-22-4 124218-98-0 124218-99-1 124219-00-7
(immunoregulating compns. contg.)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 124219-00-7 REGISTRY

SEQ3 1 Asp-Asp-Asp-Asp-Asp

=>